Agenus (AGEN) AGM 2026 summary

Opening remarks and agenda

• Emphasized the urgent need to expand immunotherapy to patients with historically unresponsive cancers, especially MSS colorectal cancer, and outlined the session's focus on clinical progress, patient access, and operational readiness.

• Highlighted the convergence of clinical development, patient access, and operational readiness as key themes for the meeting.

Financial performance review

• Reported $3.2 million in realized revenues in Q4 from the French AAC and named patient programs, reflecting growing physician and patient demand.

• Noted increasing interest and inquiries from over 30 countries, with 270 requests by end of March, indicating expanding global reach.

Board and executive committee updates

• Leadership discussed the company's mission, regulatory strategy, and operational priorities, with active participation from the CEO, CMO, and CCO.

• Announced the formalization of a medical education and medical affairs department to support physician education and real-world data collection.